Skip to main content

Over Active Bladder

1
Pipeline Programs
3
Companies
12
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Astellas
AstellasChina - Shenyang
1 program
1
solifenacinPhase 41 trial
Active Trials
NCT01318837Completed100Est. Sep 2011
BlueWind Medical
BlueWind MedicalIsrael - Herzliya
1 program
BlueWind Medical systemN/A1 trial
Active Trials
NCT02299544Completed36Est. Dec 2018
Pfizer
PfizerNEW YORK, NY
1 program
FesoterodineN/A5 trials
Active Trials
NCT01302067Completed2,012Est. Nov 2012
NCT01260311Completed508Est. Oct 2013
NCT01091519Terminated781Est. May 2012
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
PfizerFesoterodine
Astellassolifenacin
PfizerFesoterodine
PfizerFesoterodine
PfizerFesoterodine
PfizerFesoterodine
PfizerFesoterodine
PfizerFesoterodine
BlueWind MedicalBlueWind Medical system
PfizerFesoterodine
PfizerFesoterodine
PfizerFesoterodine

Clinical Trials (12)

Total enrollment: 5,313 patients across 12 trials

NCT01302067PfizerFesoterodine

A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine

Start: May 2011Est. completion: Nov 20122,012 patients
Phase 4Completed

A Study to Evaluate Response of Over Active Bladder Symptom Score to Solifenacin Treatment

Start: Apr 2010Est. completion: Sep 2011100 patients
Phase 4Completed
NCT00546637PfizerFesoterodine

Fesoterodine "add-on" Male Overactive Bladder Study

Start: Nov 2007Est. completion: Feb 2009947 patients
Phase 3Completed
NCT00220402PfizerFesoterodine

Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome

Start: Jul 2004Est. completion: Jul 2007
Phase 3Completed
NCT01042236PfizerFesoterodine

Evaluation Of The Ability Of Fesoterodine To Increase Urethral Pressure In Stress Urinary Incontinence Patients

Start: Jan 2009Est. completion: Jul 201022 patients
Phase 2Completed
NCT01161472PfizerFesoterodine

A Study to Assess the Cognitive Effects of Fesoterodine in Elderly Subjects

Start: Jul 2010Est. completion: Sep 201020 patients
Phase 1Completed
NCT00911235PfizerFesoterodine

The Effect Of Fluconazole On Pharmacokinetics Of Fesoterodine In Healthy Subjects

Start: May 2009Est. completion: Jul 200928 patients
Phase 1Completed
NCT00902187PfizerFesoterodine

A Bioequivalence Study Of 4 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects

Start: May 2009Est. completion: Jun 200936 patients
Phase 1Completed
NCT02299544BlueWind MedicalBlueWind Medical system

BlueWind Medical System for the Treatment of Patients With OAB

Start: Feb 2015Est. completion: Dec 201836 patients
N/ACompleted
NCT01260311PfizerFesoterodine

Post Marketing Surveillance Of Fesoterodine In Filipino Patients With Over Active Bladder

Start: Feb 2011Est. completion: Oct 2013508 patients
N/ACompleted
NCT01091519PfizerFesoterodine

Non-Interventional Study To Investigate Whether Information Provided To Patients Influences Their Satisfaction With Toviaz Therapy

Start: Dec 2010Est. completion: May 2012781 patients
N/ATerminated
NCT00691093PfizerFesoterodine

Study In Patients With Overactive Bladder Treated With Toviaz® After Failure Of Previous Therapy

Start: Jul 2008Est. completion: Jun 2009823 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.